levosalbutamol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	1575	34391-04-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: xopenex levalbuterol HCl levosalbutamol (-)-Salbutamol (R)-Salbutamol levalbuterol levalbuterol hydrochloride levalbuterol tartrate	The R-isomer of albuterol. Molecular weight: 239.32 Formula: C13H21NO3 CLOGP: 0.06 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 72.72 ALOGS: -2.05 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

xopenex
levalbuterol HCl
levosalbutamol
(-)-Salbutamol
(R)-Salbutamol
levalbuterol
levalbuterol hydrochloride
levalbuterol tartrate

The R-isomer of albuterol.

Molecular weight: 239.32
Formula: C13H21NO3
CLOGP: 0.06
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 72.72
ALOGS: -2.05
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	180 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	46 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.23 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
March 25, 1999	FDA	OAK PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	211.75	13.86	195	14143	91347	46580377
Chronic obstructive pulmonary disease	145.36	13.86	129	14209	57504	46614220
Infective pulmonary exacerbation of cystic fibrosis	117.11	13.86	60	14278	10747	46660977
Dyspnoea	71.73	13.86	330	14008	515218	46156506
Pneumonia	67.93	13.86	261	14077	376059	46295665
Sinusitis	61.48	13.86	128	14210	129640	46542084
Wheezing	57.08	13.86	76	14262	53310	46618414
Bronchitis	54.29	13.86	108	14230	105871	46565853
Cystic fibrosis	50.44	13.86	24	14314	3664	46668060
Product quality issue	44.80	13.86	55	14283	35593	46636131
Cough	42.47	13.86	161	14177	230088	46441636
Rheumatoid arthritis	40.11	13.86	12	14326	240203	46431521
Chest discomfort	38.07	13.86	85	14253	90184	46581540
Anaphylactic reaction	30.69	13.86	57	14281	53055	46618669
Infusion site erythema	29.60	13.86	22	14316	7620	46664104
Toxicity to various agents	28.12	13.86	15	14323	211751	46459973
Respiratory failure	28.06	13.86	78	14260	94738	46576986
Productive cough	25.11	13.86	51	14287	50664	46621060
Chest pain	23.66	13.86	112	14226	176212	46495512
Acute respiratory failure	23.09	13.86	36	14302	29102	46642622
Nasal congestion	22.20	13.86	47	14291	48066	46623658
Pulmonary function test decreased	21.89	13.86	14	14324	3806	46667918
Haemoptysis	21.65	13.86	33	14305	26156	46645568
Drug ineffective	20.71	13.86	123	14215	677715	45994009
Upper respiratory tract infection	20.51	13.86	54	14284	63502	46608222
Administration site swelling	20.39	13.86	9	14329	1156	46670568
Headache	20.25	13.86	230	14108	478122	46193602
Cardiac failure congestive	20.14	13.86	68	14270	91682	46580042
Anxiety	19.81	13.86	109	14229	181848	46489876
Pseudomonas infection	19.10	13.86	19	14319	9739	46661985
Respiratory distress	18.11	13.86	34	14304	31882	46639842
Bronchospasm	17.76	13.86	23	14315	15684	46656040
Maternal exposure during pregnancy	17.32	13.86	5	14333	102544	46569180
Drug intolerance	17.30	13.86	12	14326	147037	46524687
Infusion site swelling	16.87	13.86	14	14324	5685	46666039
Treatment failure	16.74	13.86	4	14334	93083	46578641
Hyperacusis	16.37	13.86	9	14329	1855	46669869
Heart rate increased	16.03	13.86	55	14283	74736	46596988
Dysphonia	15.98	13.86	36	14302	38378	46633346
Poor quality device used	15.32	13.86	9	14329	2103	46669621
Bronchospasm paradoxical	15.28	13.86	4	14334	102	46671622
Enterovirus infection	14.95	13.86	6	14332	608	46671116
Respiratory tract infection	14.66	13.86	30	14308	29942	46641782
Rhinitis allergic	14.54	13.86	14	14324	6894	46664830
Bronchitis chronic	13.95	13.86	11	14327	4156	46667568

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	95.86	16.96	69	5761	36105	29910543
Infective pulmonary exacerbation of cystic fibrosis	92.07	16.96	41	5789	8531	29938117
Chronic obstructive pulmonary disease	72.92	16.96	65	5765	46061	29900587
Dyspnoea	55.73	16.96	166	5664	333129	29613519
Respiratory distress	37.88	16.96	39	5791	32933	29913715
Cough	37.17	16.96	78	5752	125564	29821084
Pneumonia	36.81	16.96	145	5685	334161	29612487
Upper respiratory tract infection	30.66	16.96	32	5798	27444	29919204
Bronchospasm paradoxical	29.90	16.96	6	5824	72	29946576
Toxic optic neuropathy	29.09	16.96	9	5821	673	29945975
Status asthmaticus	26.01	16.96	7	5823	318	29946330
Respiratory failure	22.53	16.96	56	5774	100586	29846062
Sinusitis	20.95	16.96	29	5801	33316	29913332
Cystic fibrosis	18.56	16.96	9	5821	2265	29944383
Oxygen saturation decreased	17.77	16.96	31	5799	43409	29903239
Product quality issue	17.67	16.96	20	5810	18754	29927894

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000009922	Adrenergic beta2-Agonists
FDA EPC	N0000175779	beta2-Adrenergic Agonist

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Bronchospasm	indication	4386001
Acute exacerbation of asthma	indication	708038006
Bronchospasm Prevention	indication
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Ketoacidosis	contraindication	56051008
Diabetes mellitus	contraindication	73211009	DOID:9351
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Chronic myocardial ischemia	contraindication	413844008	DOID:3393

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.07	acidic
pKa2	9.46	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	Ki	5.42		CHEMBL	CHEMBL

External reference:

ID	Source
D02281	KEGG_DRUG
50293-90-8	SECONDARY_CAS_RN
4021157	VANDF
C0772501	UMLSCUI
CHEBI:8746	CHEBI
68H	PDB_CHEM_ID
123600	PUBCHEM_CID
CHEMBL1002	ChEMBL_ID
CHEMBL1201061	ChEMBL_ID
CHEMBL3989693	ChEMBL_ID
DB13139	DRUGBANK_ID
D064412	MESH_DESCRIPTOR_UI
9816	IUPHAR_LIGAND_ID
7681	INN_ID
EDN2NBH5SS	UNII
237159	RXNORM
14178	MMSL
167701	MMSL
20402	MMSL
8043	MMSL
d04427	MMSL
007763	NDDF
007764	NDDF
010710	NDDF
116090007	SNOMEDCT_US
398965008	SNOMEDCT_US
412236007	SNOMEDCT_US
426604008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4145	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4146	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4147	SOLUTION, CONCENTRATE	1.25 mg	RESPIRATORY (INHALATION)	ANDA	26 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4148	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9930	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	ANDA	31 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9931	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	ANDA	31 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9932	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	ANDA	31 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6993	SOLUTION, CONCENTRATE	1.25 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9690	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	ANDA	28 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9691	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	ANDA	28 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9692	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	ANDA	28 sections
Levalbuterol tartrate HFA inhalation	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2927	AEROSOL, METERED	45 ug	ORAL	NDA AUTHORIZED GENERIC	27 sections
Levalbuterol Inhalation Solution	Human Prescription Drug Label	1	16714-094	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol Inhalation Solution	Human Prescription Drug Label	1	16714-095	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol Inhalation Solution	Human Prescription Drug Label	1	16714-096	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Xopenex	HUMAN PRESCRIPTION DRUG LABEL	1	17478-171	SOLUTION, CONCENTRATE	1.25 mg	RESPIRATORY (INHALATION)	NDA	27 sections
Xopenex	HUMAN PRESCRIPTION DRUG LABEL	1	17478-172	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	NDA	27 sections
Xopenex	HUMAN PRESCRIPTION DRUG LABEL	1	17478-173	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	NDA	27 sections
Xopenex	HUMAN PRESCRIPTION DRUG LABEL	1	17478-174	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	NDA	27 sections
Xopenex	HUMAN PRESCRIPTION DRUG LABEL	1	21695-153	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	NDA	24 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	35573-443	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	ANDA	18 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	35573-444	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	ANDA	18 sections
Levalbuterol	HUMAN PRESCRIPTION DRUG LABEL	1	35573-445	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	ANDA	18 sections
levalbuterol inhalation	HUMAN PRESCRIPTION DRUG LABEL	1	43598-409	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
levalbuterol inhalation	HUMAN PRESCRIPTION DRUG LABEL	1	43598-410	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
levalbuterol inhalation	HUMAN PRESCRIPTION DRUG LABEL	1	43598-412	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol Inhalation Solution	Human Prescription Drug Label	1	47335-743	SOLUTION	0.31 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol Inhalation Solution	Human Prescription Drug Label	1	47335-746	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Levalbuterol Inhalation Solution	Human Prescription Drug Label	1	47335-753	SOLUTION	1.25 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Xopenex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4409	SOLUTION	0.63 mg	RESPIRATORY (INHALATION)	NDA	14 sections